Name: 5th Annual MarketsandMarkets Real-World Evidence and Life Sciences Analytics Conference
Start: 2022-10-20
End: 2022-10-21
Location: Hilton Boston Logan Airport

WHAT TO EXPECT

Regulatory view around data quality & data standards.
Leveraging RWE for improving market access.
The adoption & role of AI & ML in clinical trials.
Real-world evidence & Digital Health - The expanded role of RWE for digital health.
Panel Discussion on lessons learned from the recent results of the FDA’s
pilot program RCT DUPLICATE.
Real-World Data & Advanced Analytics.
RWE to inform decision making process in rare diseases where there is lack of evidence.

Learn about the recent trends and advancements in Real-World Evidence Generation
Engage in meaningful discussion with the most prominent industry experts and decision makers from pharmaceutical and biopharmaceutical companies who will address most critical challenges in real-world data and real-world evidence space.
Opportunity to network and exchange scientific knowledge with expert speakers from leading pharmaceutical companies, global regulators and solution providers

From pharmaceutical and Biopharmaceutical companies

Chief executives, VP’s, Directors, Global heads, Heads, Leaders, Senior Managers, Researcher, Analysts, Investigators, Scientists within the following departments-

Real-World Evidence, Real-World Data, Health Economics & Outcomes Research- HEOR, Market Access/Value Access, Clinical Outcomes, Clinical Development & research, Clinical trial and others

CONFERENCE AGENDA

Registration	08:15 - 08:55
Welcome note from MarketsandMarkets!	08:55 - 09:00
Opening Remarks from the Chairman Prasun Mishra, Founding Director, Chairman of the Board, Agility Pharmaceuticals	09:00 - 09:05
Demonstrating Drug Value to Enable Efficient Reimbursement Charles Makin , Head of RWE, Boehringer-Ingelheim	09:05 - 09:40
Strategies for leveraging Real-World Data in the Pharmaceutical Landscape Sunil Dravida, Global Head of RWD Center of Excellence,, Takeda	09:40 - 10:15
Delivering on the Promise of RWD to Advance Health Equity: Opportunities, Challenges and Case Studies Jessica Paulus, VP of Research, OM1,Inc	10:15 - 10:50
Morning Refreshments \| One-to-One Networking Meetings	10:50 - 11:40
Using RWE in Drug Development Pipeline Xiaoyun (Lucy) Pan, Senior Director, Oncology Real World Evidence, Bayer	11:40 - 12:15
Integrated Data – Greater than the sum of its parts? Nathan Hill, Director, Real World Evidence Strategy and Innovations, BMS	12:15 - 12:50
Let’s Get Direct: How working directly with patients optimizes delivery of complete RWD Kristen Hahn, PhD, MPH Head of RWE Research, Picnic Health	12:50 - 13:25
Lunch \| One-to-One Networking Meetings	13:25 - 14:25
Real World Data and Precision Medicine Jennifer Webster, Senior Director, RWE Scientist Oncology Team Lead, Pfizer	14:25 - 15:00
How Artificial Intelligence is Enhancing Real-World Data, Evidence, and the future of Precision Medicine Prasun Mishra, Founding Director, Chairman of the Board, Agility Pharmaceuticals	15:00 - 15:35
How to Leverage RWE to Improve Market Access and to Inform Decision Making Process Huan Huang, Senior Director, Healh Economics & Outcomes Research (HEOR), G1 Therapeutics, USA	15:35 - 16:10
Breakout Session: Precision Medicine: The Way Forward! Prasun Mishra, Founding Director, Chairman of the Board, Agility Pharmaceuticals	16:10 - 16:45
Closing remarks from the chairperson! Prasun Mishra, Founding Director, Chairman of the Board, Agility Pharmaceuticals	16:45 - 16:45
Drinks Reception and Networking \| Evening Refreshments	16:45 - 16:45
End of Day 1	16:45 - 16:45

Registration	08:15 - 08:55
Welcome Note from MarketsandMarkets!	08:55 - 09:00
Opening Remarks from the Chairman! Andrew Stewart, Head of RWE and Behavioral Science - Consumer Healthcare, Sanofi	09:00 - 09:05
The Importance of Metadata Quality and Completeness for Real World Evidence and Insight Generation Jennifer Webster, Senior Director, RWE Scientist Oncology Team Lead, Pfizer	09:05 - 09:40
Strategic use RWE to Address Uncertainty Related to Decision Making in Rare Disease Joel Iff, Senior Director Global Market Access, Sarepta Therapeutics, USA	09:40 - 10:15
Morning Refreshments \| One-to-One Networking Meetings	10:15 - 11:05
PANEL DISCUSSION: Lessons learned from the recent results of the FDA’s pilot program RCT- DUPLICAT	11:05 - 11:50
How Science, Technology, and Regulations are Converging to Transform the Role of RWE in Healthcare Decision-Making Vishvas Garg, Sr. Director, TA Lead, HEOR, AbbVie	11:50 - 12:25
Understanding the patient/payer perspective: Making evidence relevant Andrew Stewart, Head of RWE and Behavioral Science - Consumer Healthcare, Sanofi	12:25 - 13:00
Closing remarks from the chairperson Andrew Stewart, Head of RWE and Behavioral Science - Consumer Healthcare, Sanofi	13:00 - 13:00
Lunch \| One-to-One Networking Meetings	13:00 - 14:00
End of Conference	14:00 - 14:00